Company / Return on Equity (ROE)
OptimizeRx Corp Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-17.2%
FY2025
5-year range
-17.2% / 0.3%
FY2021-FY2025
Trend
-23.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
OptimizeRx Corp reports negative total equity of -17.2% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-17.2% in FY2025 with a 5-year CAGR of -10.2%.
Declined from -9.1% to -17.2% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -17.5pp
- 5-Year Change
- -10.2pp
- 10-Year Change
- -
Key checks
Key Insights
- OptimizeRx Corp's return on equity (roe) has declined for 3 consecutive years.
- In FY2025, return on equity (roe) decreased 23.8% year-over-year.
- Peak return on equity (roe) was recorded in FY2019.
- Lowest return on equity (roe) in the period was in FY2018.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -17.2% | -23.8% |
| FY2024 | -13.9% | -53.0% |
| FY2023 | -9.1% | -3227.6% |
| FY2022 | 0.3% | +105.9% |
| FY2021 | -4.9% | +29.7% |
| FY2020 | -7.0% | -669.1% |
| FY2019 | 1.2% | +103.6% |
| FY2018 | -33.8% | -71.7% |
| FY2017 | -19.7% | -195.8% |
| FY2016 | -6.7% | +70.1% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026